Vertex Pharmaceuticals has grown from a $7.5 billion market cap to over $120 billion as it’s commercialized several products.

Gene editing technologies have cemented their place as a valued method in the biological toolkit used by researchers around the globe.

The potential for cell and gene therapies is growing, offering groundbreaking treatments for rare genetic disorders and ...

Equity markets may be struggling because of President Donald Trump's current economic policies, but that doesn't mean ...

Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex ...

Gene therapy companies have faced numerous setbacks over the last few years. What will it take for gene therapies to fulfill ...

Vertex Pharmaceuticals sees early success with Journavx painkiller, potential revenue growth from drug and gene therapy.

As biotech investors know, companies in the industry can sometimes earn significant returns in relatively short periods, like ...

Is a recession coming? Our economic outlook seems increasingly gloomy due to President Trump's trade policies. Though things ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.